MapTechnology
Core Technology I
- A breakthrough in eliminating solid tumors
- A major limitation of adoptive cell immunotherapy is its insufficient therapeutic efficacy, even with the use of genetically modified chimeric antigen receptor (CAR)-T and natural killer (NK) cells.
Our platform enables the production of NK-like cells that effectively eliminate solid tumors, without any genetic modification.
Distinctive
Features
Rapid and Effective
Cancer Killer
Unlike NK cells from well-known manufacturers, GAIA NK-like cells express multiple chemokine receptors and adhesion molecules that are essential for the accumulation and retention of these cells in solid tumors.
Unlike CAR-T cells, GAIA NK-like cells can kill cancer cells and eliminate solid tumors as quickly as within 1-48 hours.
Distinctive
Features
Off-the-shelf allogeneic cells,
without gene modification
Similar to NK cells from well-known manufacturers, GAIA NK-like cells are generated from allogeneic cells with a donor recipient human leukocyte antigen (HLA)/killer-cell immunoglobulin-like receptor (KIR) mismatch.
However, unlike allogeneic CAR-T cells, GAIA NK-like cells are produced without any genetic modification.
Distinctive
Features
Ready-to-use formulations
GAIA NK-like cells are ready to use and simply need to be resuspended for administration.
After being resuspended, GAIA NK-like cells maintain their cytotoxic activity and viability for over 4 hours at room temperature.
Core Technology II
and activating peptide
- A peptide-based platform to generate
GAIA NK-like cells targeting a variety of tumors - GAAAP enables the generation of GAIA NK-like cells that maintain their active state in vivo and specifically target cancer cell-expressed proteins.
Distinctive
Features
Production of a variety of
GAIA NK-like cells
appropriate for each target
By modulating the GAAAP, we can produce a wide array of GAIA NK-like cells armed with antibodies that are available on the market.
Distinctive
Features
Reduction of on target off
tumor toxicity
GAAAP allows antibody-expressing GAIA NK-like cells to dramatically reduce the on target off tumor toxicity caused by antibody-dependent opsonization.